Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01072734
Other study ID # P090104
Secondary ID
Status Completed
Phase Phase 2
First received February 19, 2010
Last updated October 11, 2010
Start date September 2009
Est. completion date February 2010

Study information

Verified date October 2010
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Annual influenza vaccination is recommended in patients with systemic lupus erythematosus (SLE). However some concerns remain about vaccination and the risk of lupus flare


Description:

SLE is a chronic autoimmune disease associated with the production of pathogenic anti-nuclear autoantibodies (ANAs) and characterized by the loss of self tolerance and the overexpression of B cells, leading to a high immunoglobulin production, 90% being autoantibodies.

There have been concerns about the safety of vaccination in patients with autoimmune diseases as it has been hypothesised that stimulation of the immune system via vaccination may lead to an increase in disease activity. Furthermore, SLE patients display a variety of immune dysfunctions which may influence their response to influenza vaccination.

Studies indicate that, although influenza vaccination in SLE may generate autoimmune phenomena, no clinically significant increase in SLE disease activity can be expected. Therefore, influenza vaccination can be considered safe in quiescent SLE, in accordance with previous reviews on this subject

The aim of this study is to evaluate if the level of CXCR4 on leucocytes of patients with SLE could be a good prognostic marker for the efficacy and the safety of influenza vaccine in SLE patients. For that purpose, we will assay in lupus patients the cellular level of CXCR4 before and after administration of influenza vaccine and correlate the expression levels of CXCR4 with: 1) the evolution of clinical and biological signs of autoimmunity and 2) the humoral immune response towards influenza. If influenza vaccine has not been associated so far with increased risk of lupus flare, it is important to determine if patients with elevated leucocytes levels of CXCR4, (due to the impact of this molecule in humoral immunity), are more at risk of vaccine side effects particularly of autoimmune origin.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date February 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria :

- 18 years of age and older

- informed consent signed

- LES patients who meet the American College of Rheumatology (ACR) diagnostic criteria of SLE

- Patient able to attend all visit schedule during the month following influenza vaccine administration

- Clinical examination performed prior final inclusion with results communicated to the patient

Exclusion criteria :

- For women, being pregnant or positive pregnancy test

- Positive for HCV, HIV and HBV

- Patient treated with rituximab (anti-CD20) or stopped for less than a year.

- Patient for whom a treatment majorization is suspected within the month following influenza vaccine administration.

- Hypersensitivity to active substances, eggs and to one of the vaccine components

- Other vaccinations within the last 30 days before the inclusion at J0

- Administration of blood products such as immunoglobulins within the last 90 days before J0

- Progressive cancer, cirrhoses

- Acute severe illness within the last 30 days before inclusion at J0

- Patient non affiliated to a health social security system

- Planned participation to another clinical study during the present study period

- patient deprived of freedom by an administrative or court order

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vaccine
Influenza vaccine

Locations

Country Name City State
France CIC Vaccinologie Hopital Cochin Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The expression of CXCR4 on B cells, T cells, monocytes and granulocytes by FACS on LES patients will be measured the day of the vaccination and then 7 and 30 days post-vaccination 7 and 30 days post-vaccination
Secondary The biological signs of autoimmunity will be followed using the routine laboratory tests such as the complement exploration and the detection of total anti-nuclear antibodies detection one year after
See also
  Status Clinical Trial Phase
Completed NCT04461158 - CCCR Lupus Patient Navigator Program N/A
Completed NCT02006784 - Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE) N/A
Completed NCT03626311 - Omega-3 Replacement With Krill Oil in Disease Management of SLE N/A
Withdrawn NCT02779153 - Acthar SLE (Systemic Lupus Erythematosus) Phase 4
Completed NCT01992666 - GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus N/A
Completed NCT00779194 - Prospective Study of Rapamycin for the Treatment of SLE Phase 2
Recruiting NCT00582881 - Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Terminated NCT02811094 - LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse N/A
Recruiting NCT05458622 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol Phase 3
Recruiting NCT06144710 - SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus Phase 1
Completed NCT03031925 - Detection of Annexin A2 in Systemic Lupus Erythematosus N/A
Not yet recruiting NCT06420154 - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases N/A
Recruiting NCT02782039 - Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
Recruiting NCT05567198 - Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Recruiting NCT05747651 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
Recruiting NCT03030976 - A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) Phase 1
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT05724940 - Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
Recruiting NCT06032923 - Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus Phase 1/Phase 2